Die kostenlosen ARIVA.DE Börsen-Dienste:
Bleiben Sie immer informiert und melden Sie sich jetzt für die Newsletter von ARIVA.DE an!
Jetzt kostenlos abonnieren

Investor 2019: Vassago

Cashbestand:
787,90 €
Platz:
Gesamtwert mit Cash:
112.335,78 € (28.04.20 10:00)
Börsenspiel beendet. Diese Werte werden nicht mehr aktualisiert.
Kurse zum Spielende    

News

Zeit
Titel
Wertpapier
 
Mi Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics Inc
Di Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
Myriad Genetics Inc
07.06.24 Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Inc
03.06.24 Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
Puma Biotechnology Inc
02.06.24 Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
Puma Biotechnology Inc
30.05.24 Nektar Management to Present at Upcoming Investor Conferences
Nektar Therapeutics Inc
28.05.24 Puma Biotechnology to Join Russell 3000 Index
Puma Biotechnology Inc
23.05.24 Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
Puma Biotechnology Inc
09.05.24 Nektar Therapeutics Reports First Quarter 2024 Financial Results
Nektar Therapeutics Inc
02.05.24 Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology Inc
02.05.24 Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
Nektar Therapeutics Inc
18.04.24 Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Puma Biotechnology Inc
03.04.24 Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Inc
22.03.24 Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Therapeutics Inc
20.03.24 Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Puma Biotechnology Inc
05.03.24 Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
Nektar Therapeutics Inc
04.03.24 Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
Nektar Therapeutics Inc
04.03.24 Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
Nektar Therapeutics Inc
27.02.24 Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
Nektar Therapeutics Inc
26.02.24 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
Nektar Therapeutics Inc
18.01.24 Thinking about buying stock in Marpai, Phunware, Spirit Airlines, BigBear.ai, or Puma Biotechnology?
Puma Biotechnology Inc
03.01.24 Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Nektar Therapeutics Inc
11.12.23 Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
Nektar Therapeutics Inc
07.11.23 Nektar Therapeutics Reports Third Quarter 2023 Financial Results
Nektar Therapeutics Inc
31.10.23 Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
Nektar Therapeutics Inc
13.10.23 Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
Nektar Therapeutics Inc
02.10.23 Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
Nektar Therapeutics Inc
28.09.23 BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD
Myriad Genetics Inc
27.09.23 Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
Nektar Therapeutics Inc
13.09.23 Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics Inc
Mi
Nektar Therapeutics Inc
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Di
Myriad Genetics Inc
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
07.06.24
Puma Biotechnology Inc
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03.06.24
Puma Biotechnology Inc
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
02.06.24
Puma Biotechnology Inc
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
30.05.24
Nektar Therapeutics Inc
Nektar Management to Present at Upcoming Investor Conferences
28.05.24
Puma Biotechnology Inc
Puma Biotechnology to Join Russell 3000 Index
23.05.24
Puma Biotechnology Inc
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
09.05.24
Nektar Therapeutics Inc
Nektar Therapeutics Reports First Quarter 2024 Financial Results
02.05.24
Puma Biotechnology Inc
Puma Biotechnology Reports First Quarter Financial Results
02.05.24
Nektar Therapeutics Inc
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
18.04.24
Puma Biotechnology Inc
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
03.04.24
Puma Biotechnology Inc
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
22.03.24
Nektar Therapeutics Inc
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
20.03.24
Puma Biotechnology Inc
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
05.03.24
Nektar Therapeutics Inc
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
04.03.24
Nektar Therapeutics Inc
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
04.03.24
Nektar Therapeutics Inc
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
27.02.24
Nektar Therapeutics Inc
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
26.02.24
Nektar Therapeutics Inc
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
18.01.24
Puma Biotechnology Inc
Thinking about buying stock in Marpai, Phunware, Spirit Airlines, BigBear.ai, or Puma Biotechnology?
03.01.24
Nektar Therapeutics Inc
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
11.12.23
Nektar Therapeutics Inc
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
07.11.23
Nektar Therapeutics Inc
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
31.10.23
Nektar Therapeutics Inc
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
13.10.23
Nektar Therapeutics Inc
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
02.10.23
Nektar Therapeutics Inc
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
28.09.23
Myriad Genetics Inc
BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD
27.09.23
Nektar Therapeutics Inc
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
13.09.23
Nektar Therapeutics Inc
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Musterdepot - © Ismagilov / Shutterstock

Das kostenlose Musterdepot von ARIVA.DE

Bei einem niedrigen Kurs einsteigen, bei einem hohen Kurs wieder verkaufen – es klingt einfach, an der Börse Erfolg zu haben. Tatsächlich brauchen Aktionäre gute Nerven, wenn die Kurse auf und ab schwanken. Realistische Anlageziele, eine klare Linie bei der Auswahl der Wertpapiere und das clevere Einsetzen bestimmter Ordertypen gehören zum Handwerk beim Handel mit Wertpapieren.

Um ein Gefühl dafür zu bekommen, welche Strategien in welchen Börsenphasen fruchten, können Nutzerinnen und Nutzer bei ARIVA.DE kostenlos ein Musterdepot anlegen und Wertpapiere wie Anleihen, Aktien, Derivate oder Fonds virtuell im Musterdepot handeln. Die Orders werden zum Schein ausgeführt und finden sich dann in einem virtuellen Musterdepot, ohne dass die Papiere tatsächlich ge- oder verkauft werden. So lassen sich Anlagestrategien testen, ohne Geld zu riskieren.

Viele Nutzer bauen auf ARIVA.DE im Musterdepot ihr reales Depot nach, das ein Broker für sie führt. Grund: Beim Musterdepot auf ARIVA.DE ist jede Position mit den zugehörigen News, dem Forum und der Profilseite verlinkt. Über die Aktien auf dem Laufenden zu bleiben, ist durch das Musterdepot sehr einfach. Möglich ist es auf ARIVA.DE auch, interessante Wertpapiere in eine Watchlist aufzunehmen, um ihre Entwicklung im Auge zu behalten. Nutzer können dabei Kursgrenzen vorgeben und sich bei Erreichen benachrichtigen lassen.

Übrigens: Wer ein virtuelles Musterdepot im Rahmen eines der Börsenspiele von ARIVA.DE eröffnet, hat einen weiteren Lerneffekt: Beim Börsenspiel wird ein Budget vorgegeben, und für jede Transaktion fallen virtuelle Gebühren an. Das macht den „Scheinhandel“ noch realistischer.